Allopurinol, is the Next General Drug for Chronic Heart Failure? A Review Based on 19 Clinical Trials

Zhu, Yan

doi:10.4172/2153-2435.1000360

Cited by 1 publication

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3,4,6-12 Also it has been shown a trend toward decreased cardiovascular events and mortality with allopurinol use in many clinical studies. 8,18 These remarkable therapeutic values of this drug in patients with HF seems to be independent from its uric acid lowering effects.…”

Section: Discussionmentioning

confidence: 99%

“…Most of the studies in this regard are small studies which use different doses of allopurinol and it has been shown that the effect of allopurinol on endothelial function and UA lowering in HF is dose dependent and the drug is most useful with high doses or in patients with elevated UA level. 3,4,6,8,12,20 For example, in the OPT-CHF trial, Hare et al reported that treatment with oxypurinol (the active metabolite of allopurinol) was associated with improved clinical status and survival only in moderate to severe HFrEF patients with hyperuricemia (UA>9.5 mg/dL). 8 However, Baldus et al showed intravenous oxypurinol could have positive inotropic effect independent to endogenous release of catecholamines in patients with HFrEF who had normal UA level.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Safety and effect of high dose allopurinol in patients with severe left ventricular systolic dysfunction

Ramandi¹,

Maleki²,

Alizadehasl³

et al. 2017

J Cardiovasc Thorac Res

View full text Add to dashboard Cite

Introduction: Allopurinol used in the treatment of gout has been shown to improve the vascular endothelial dysfunction and reduce the dysfunction of the failing heart. This study was done to evaluate the effect and safety of allopurinol in non-hyperuricemic patients with chronic severe left ventricular (LV) dysfunction. Methods: In this study, 35 consecutive cases of non-hyperuricemic patients with chronic heart failure who had severe LV systolic dysfunction (ejection fraction of less than 35%) and were on optimal guideline directed medical therapies for at least 3 months were included. Allopurinol was administered with the dose of 300 mg po daily for 1 week and then it was up-titrated to a dose of 600 mg po daily for 3 months. Six minute walk test, strain imaging, laboratory testing were done for every patient at baseline and after 3 months treatment with allopurinol. Results: In this study 30 heart failure (HF) patients with a mean age of 49.3 ± 14.4 years old were evaluated. No adverse effects were reported except for one case of skin rash after 4 days treatment which was excluded from the study. Study showed significant improvement of six minute walk test of the patients from 384.5 ± 81.5 meters to 402.8 ± 89.6 meters and the global longitudinal peak strain (P < 0.001). There was also significant decrease in the level of erythrocyte sedimentation rate and N-terminal pro-brain natriuretic peptide (NT-proBNP) after 3 months. Conclusion: Allopurinol could be of benefit in non-hyperuricemic patients with severe LV systolic dysfunction without significant adverse effects. Randomized clinical trials are needed in future to confirm the results.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Safety and effect of high dose allopurinol in patients with severe left ventricular systolic dysfunction

Ramandi¹,

Maleki²,

Alizadehasl³

et al. 2017

J Cardiovasc Thorac Res

View full text Add to dashboard Cite

show abstract

Allopurinol, is the Next General Drug for Chronic Heart Failure? A Review Based on 19 Clinical Trials

Abstract: Introduction: Allopurinol, a xanthine oxidase inhibitor, has been reported to have therapeutic value in patients with chronic heart failure, besides its routine effect of decreasing uric acid level.

Cited by 1 publication

References 29 publications

Safety and effect of high dose allopurinol in patients with severe left ventricular systolic dysfunction

Safety and effect of high dose allopurinol in patients with severe left ventricular systolic dysfunction

Contact Info

Product

Resources

About